NanoViricides (NNVC) announced that it has engaged a clinical research organization to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline.
NanoViricides (NNVC) announced that it has engaged a clinical research organization to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline.